nach oben

Erschienen in:

01.03.2023 | Research Letter

Optimizing Safety Surveillance for COVID-19 Vaccines at the Swedish Medical Products Agency

verfasst von: Karl Mikael Kälkner, Anders Sundström, Marja-Leena Nurminen, Maria Larsson, Rickard Ljung, Veronica Arthurson

Erschienen in: Drug Safety | Ausgabe 3/2023

Einloggen, um Zugang zu erhalten

Auszug

Dear Editor, …

Persson I, Granath F, Askling J, Ludvigsson JF, Olsson T, Feltelius N. Risks of neurological and immune-related diseases, including narcolepsy, after vaccination with Pandemrix: a population- and registry-based cohort study with over 2 years of follow-up. J Intern Med. 2014;275(2):172–90. https://doi.org/10.1111/joim.12150. (Epub 2013 Nov 10).CrossRefPubMed

Ljung R, Sundström A, Grünewald M, Backman C, Feltelius N, Gedeborg R, et al. The profile of the COvid-19 VACcination register SAFEty study in Sweden (CoVacSafe-SE). Ups J Med Sci. 2021;2021:126. https://doi.org/10.48101/ujms.v126.8136.CrossRef

Karlstad Ø, Hovi P, Husby A, Tommi H, Selmer RM, Pihlström N, et al. SARS-CoV-2 vaccination and myocarditis in a Nordic cohort study. JAMA Cardiol. 2022;7(6):600–12. https://doi.org/10.1001/jamacardio.2022.0583.CrossRefPubMedPubMedCentral

Hviid A, Nieminen TA, Pihlström P, Gunnes N, Dahl J, Karlstad Ø, et al. Booster vaccination with SARS-CoV-2 mRNA vaccines and myocarditis risk in adolescents and young adults: a Nordic cohort study of 8.9 million residents. 2023. https://medrxiv.org/cgi/content/short/2022.12.16.22283603v1. Accessed 27 Jan 2023.

Oosterhuis I, Scholl J, van Puijenbroek E, Kant A, van Hunsel F. Optimizing safety surveillance for COVID-19 vaccines at the National Pharmacovigilance Centre Lareb: one year of COVID-19 vaccine experience. Drug Saf. 2022;2022:1–11. https://doi.org/10.1007/s40264-022-01253-5.CrossRef

Amaro C, Monteiro C, Duarte AP. COVID-19 vaccines adverse reactions reported to the pharmacovigilance unit of Beira Interior in Portugal. J Clin Med. 2022;11(19):5591. https://doi.org/10.3390/jcm11195591.CrossRefPubMedPubMedCentral

Titel: Optimizing Safety Surveillance for COVID-19 Vaccines at the Swedish Medical Products Agency
verfasst von: Karl Mikael Kälkner
Anders Sundström
Marja-Leena Nurminen
Maria Larsson
Rickard Ljung
Veronica Arthurson
Publikationsdatum: 01.03.2023
Verlag: Springer International Publishing
Erschienen in: Drug Safety / Ausgabe 3/2023
Print ISSN: 0114-5916
Elektronische ISSN: 1179-1942
DOI: https://doi.org/10.1007/s40264-023-01275-7

The COVID-19 Vaccines International Pregnancy Exposure Registry (C-VIPER): Protocol and Methodological Considerations

Original Research Article

Correction: Compliance with Prescribing and Dispensing Conditions for Valproate and Related Substances in Girls and Women of Childbearing Potential: A Survey of Community Pharmacists in France

Open Access
Correction

What Factors Make EU Regulators Want to Communicate Drug Safety Issues Related to SGLT2 Inhibitors? An Online Survey Study

Open Access
Original Research Article

Deliberate Self-Poisoning: Real-Time Characterization of Suicidal Habits and Toxidromes in the Food and Drug Administration Adverse Event Reporting System

Open Access
Original Research Article

Use of Structured Electronic Health Records Data Elements for the Development of Computable Phenotypes to Identify Potential Adverse Events Associated with Intravenous Immunoglobulin Infusion

Original Research Article

Correction to: Individual Case Safety Report Replication: An Analysis of Case Reporting Transmission Networks

Open Access
Correction

Springer Medizin

Optimizing Safety Surveillance for COVID-19 Vaccines at the Swedish Medical Products Agency

Auszug

Weitere Artikel der Ausgabe 3/2023

The COVID-19 Vaccines International Pregnancy Exposure Registry (C-VIPER): Protocol and Methodological Considerations

Correction: Compliance with Prescribing and Dispensing Conditions for Valproate and Related Substances in Girls and Women of Childbearing Potential: A Survey of Community Pharmacists in France

What Factors Make EU Regulators Want to Communicate Drug Safety Issues Related to SGLT2 Inhibitors? An Online Survey Study

Deliberate Self-Poisoning: Real-Time Characterization of Suicidal Habits and Toxidromes in the Food and Drug Administration Adverse Event Reporting System

Use of Structured Electronic Health Records Data Elements for the Development of Computable Phenotypes to Identify Potential Adverse Events Associated with Intravenous Immunoglobulin Infusion

Correction to: Individual Case Safety Report Replication: An Analysis of Case Reporting Transmission Networks

Springer Medizin

Auszug

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

The COVID-19 Vaccines International Pregnancy Exposure Registry (C-VIPER): Protocol and Methodological Considerations

Correction: Compliance with Prescribing and Dispensing Conditions for Valproate and Related Substances in Girls and Women of Childbearing Potential: A Survey of Community Pharmacists in France

What Factors Make EU Regulators Want to Communicate Drug Safety Issues Related to SGLT2 Inhibitors? An Online Survey Study

Deliberate Self-Poisoning: Real-Time Characterization of Suicidal Habits and Toxidromes in the Food and Drug Administration Adverse Event Reporting System

Use of Structured Electronic Health Records Data Elements for the Development of Computable Phenotypes to Identify Potential Adverse Events Associated with Intravenous Immunoglobulin Infusion

Correction to: Individual Case Safety Report Replication: An Analysis of Case Reporting Transmission Networks